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The phosphoinositide phosphatase synaptojanin 1
(SYNJ1) is a key regulator of synaptic function. We
first testedwhetherSYNJ1 contributes to phenotypic
variations in familial Alzheimer’s disease (FAD) and
show that SYNJ1 polymorphisms are associated
with age of onset in both early- and late-onset human
FAD cohorts. We then interrogated whether SYNJ1
levels could directly affect memory. We show that
increased SYNJ1 levels in autopsy brains from adults
with Down syndrome (DS/AD) are inversely corre-
lated with synaptophysin levels, a direct readout of
synaptic integrity. We further report age-dependent
cognitive decline in a mouse model overexpressing
murine Synj1 to the levels observed in human spo-
radic AD, triggered through hippocampal hyperexcit-
ability and defects in the spatial reproducibility of
place fields. Taken together, our findings suggest
that SYNJ1 contributes to memory deficits in the
aging hippocampus in all forms of AD.INTRODUCTION
Synaptic function is under the rigorous control of phosphoi-
nositide turnover, and phosphatidylinositol-4,5-bisphosphateCe
This is an open access article under the CC BY-N(PtdIns[4,5]P2) is particularly important in this process (Di Paolo
et al., 2004). The PtdIns(4,5)P2 phosphatase synaptojanin 1
(Synj1) is a key regulator of synaptic vesicle endocytosis and
reavailability on the pre-synaptic side (Cremona et al., 1999;
Kim et al., 2002; Mani et al., 2007; McPherson et al., 1996; Ver-
streken et al., 2003), while on the post-synaptic side, it controls
the endocytosis of a-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) receptors (Gong and De Camilli, 2008).
A body of literature supports the importance of SYNJ1 in
neurodegenerative disorders, including Alzheimer’s disease
(AD). Clinically, AD is presented with memory loss and spatial
disorientation. Neuropathology hallmarks of this disorder include
amyloid plaques, composed primarily of Ab peptides that result
from the sequential cleavage of the amyloid precursor protein
(APP), and neurofibrillary tangles of hyperphosphorylated Tau
(Querfurth and LaFerla, 2010). The three forms of AD—familial
AD (FAD), Down syndrome-related AD (DS/AD), and sporadic
AD (SAD)—share common clinical and neuropathology signa-
tures. Although early-onset FAD is caused by mutations in the
APP, PSEN1, or PSEN2 gene (Reitz et al., 2011) and DS/AD is
due to triplication of human chromosome 21 (Hsa21) (Antonara-
kis, 2017;Wiseman et al., 2015), themost potent genetic risk fac-
tor for SAD is the ε4 allele of the APOE gene (APOE4) (Lambert
et al., 2013; Strittmatter et al., 1993).
SYNJ1 was reported to be crucial for the enlargement of early
endosomes (Cossec et al., 2012), one of the earliest cellular phe-
notypes associated with AD, observed before amyloid accumu-
lation and cognitive decline (Cataldo et al., 2000). Enlargedll Reports 23, 2967–2975, June 5, 2018 ª 2018 The Authors. 2967
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Association of SNPwithin SYNJ1Genewith Age at Onset andMemory Scores in a Cohort of Caribbean Hispanic Families with
the PSEN1-G206A Mutation
SNP Location (bp)
Age at Onseta Global Memoryb Long-Term Recallb Delayed Recallb
Beta p Value Beta p Value Beta p Value Beta p Value
21:34004976 34,004,976 0.77 0.6602 5.90 0.0397c 6.81 0.0083c 1.04 0.0504
21:34006054:G:T 34,006,054 14.91 0.0094c 9.88 0.3092 5.71 0.5150 1.45 0.4203
21:34012999 34,012,999 0.22 0.8909 6.46 0.0137c 7.14 0.0024c 1.10 0.0230c
21:34019201 34,019,201 16.14 0.0061c 7.06 0.5553 6.84 0.5278 3.00 0.1862
21:34041167 34,041,167 10.23 0.0010c 2.94 0.6074 1.23 0.8125 0.21 0.8402
rs200644223:34057206:
ACGGCCGGG:A
34,057,206–34,057,214 0.98 0.7395 15.13 0.0004c 11.55 0.0029c 2.14 0.0066c
21:34078985 34,078,985 22.46 0.0050c 0.09 0.9939 4.05 0.7115 2.39 0.2821
See also Figure S2 and Tables S1 and S2 for additional information.
aCovariates included AD, sex, PSEN1-G206A, education, APOE4, and principal components (PC1, PC2, and PC3). Age at onset is defined as age at
onset for affected individuals and age at last examination for unaffected individuals (see text for details).
bCovariates included age at onset, sex, education, APOE4, and principal components (PC1, PC2, and PC3).
cp < 0.05.endosomes are present in neurons of APOE4 carriers (Cataldo
et al., 2000) as well as in fibroblasts and lymphocytes from indi-
viduals with DS and SAD (Corlier et al., 2015; Cossec et al.,
2012). C99, the C-terminal APP fragment resulting from the ac-
tivity of b-secretase, has been reported to be required for early
endosomal enlargement (Jiang et al., 2010). Importantly though,
overexpressing APP alone is not sufficient to alter endosomal
size (Cataldo et al., 2003), and endosomal size is unaffected in
APP microduplications (Cossec et al., 2012). However, Synj1
overexpression alone is sufficient to produce enlarged endo-
somes in the brain of transgenic mice (Cossec et al., 2012),
and SYNJ1 trisomy results in increased endosomal size in cell
lines derived from individuals with partial or full trisomy of
Hsa21 (Cossec et al., 2012). In addition, SYNJ1 has also been
linked to amyloid toxicity. Oligomers of Ab peptides disrupt
PtdIns(4,5)P2 metabolism in cultured primary cortical neurons,
and genetically decreasing Synj1 levels protects from the inhib-
itory effect of Ab oligomers on hippocampal long-term potentia-
tion in brain slices (Berman et al., 2008).
A recent study reported that APOE4 carriers show increased
levels of SYNJ1 compared with non-carriers (Zhu et al., 2015).
SYNJ1 is encoded by SYNJ1, mapping to Hsa21 (Cremona
et al., 2000), and is increased in individuals with DS and DS/AD
(Arai et al., 2002; Martin et al., 2014). SYNJ1 levels are thus
elevated in individuals at high risk for developing SAD and
DS/AD, but very little is known on a potential role for synaptojanin
1 in FAD. To our knowledge, only indirect evidence in model sys-
tems has currently been published. Specifically, it has been
reported that PtdIns(4,5)P2 metabolism is disrupted in cells ex-
pressing FAD-mutant forms of presenilin 1 (Landman et al.,
2006), and earlier studies support that genetically decreasing
Synj1 levels rescues cognitive deficits in murine models of FAD
(McIntire et al., 2012; Zhu et al., 2013), although the mechanisms
involved are still controversial.
The present study addresses whether SYNJ1 is associated
with human FAD. It also explores whether elevated levels of
SYNJ1 directly affect cognition in an age-dependent manner.
Our work, combining human genetics, human autopsy brain2968 Cell Reports 23, 2967–2975, June 5, 2018samples, and behavior and in vivo electrophysiology studies in
a transgenic mouse model overexpressing murine Synj1,
Tg(Synj1) (Voronov et al., 2008), strongly supports that SYNJ1
plays a role in the function of place cells in the aging hippocam-
pus, with critical implications for memory deficits in all three
forms of AD and their possible treatment.
RESULTS
Variants of SYNJ1 Are Associated with Memory
Performance in FAD
Individuals with DS/AD (Martin et al., 2014) and APOE4 carriers
(Zhu et al., 2015) show increased levels of SYNJ1. We thus tar-
geted SYNJ1 as a candidate gene that may contribute to pheno-
typic variations in FAD. Specifically, we examined whether
SYNJ1 was associated with memory performance and age of
onset in early-onset FAD by testing a cohort of Caribbean His-
panic families with thePSEN1-G206Amutation (Table S1) (Athan
et al., 2001; Lee et al., 2015). Intriguingly, we observed a gene-
wise association of SYNJ1 with age of onset of AD (p = 0.0195)
and long-term recall performance (p = 0.0443) in this cohort
(Table S2). Our subsequent SNP analysis within SYNJ1, based
on whole-genome sequencing (WGS) data, yielded four SNPs
that were significantly associated with age of onset (p < 0.01;
Table 1). Furthermore, we observed three additional SNPs asso-
ciated with long-term recall scores and global memory scores
(p < 0.05; Table 1).
We then determined whether the observed effect was present
in late-onset FAD, a form of the disease defined by having multi-
ple family members affected with late-onset AD (Romas et al.,
2002; Zhao et al., 2013), by extending our study to the
EFIGA cohort (Lee et al., 2011; Romas et al., 2002) (Table S1).
Because the EFIGA dataset lacked WGS data, we analyzed the
candidate SYNJ1 region (bp 34,004,97634,078,985) identified
from our early-onset FAD results, using seven tagSNPs that
were found to be significant from the genome-wide association
study (GWAS) dataset available for the EFIGA cohort (Figure S1
and Table S3). Our subsequent sliding-window haplotype
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.analysis indicated that window 5 in a 3-mer analysis (bp
34,020,786–34,027,774) and window 4 in a 4-mer approach (bp
34,020,653–34,027,774) were the primary candidates for
harboring the variant(s) that contribute to age of onset of AD
(Table 2). Furthermore, we observed that carriers of the minor
haplotype (AGA or AAGA) were protected against AD, as their
age of onset was delayed by 8–10 years on average (Table 2).
The effect ofAPOE4 on age at onsetwas not significant. Our find-
ings in human cohorts thus support an association ofSYNJ1with
both early-onset and late-onset FAD.
To determine whether the candidate SNPs we identified in
early-onset FAD may affect SYNJ1 expression in the brain, we
examined the expression quantitative trait loci (eQTL) data in
the GTEx Portal, restricting our analysis to the tissues in the fron-
tal cortex. In the frontal cortex, we found that, on the basis of 129
tissue samples, rs2833943 located at 34,041,650 bp and
rs66528773 located at 34,080,468 bp were differentially ex-
pressed (p = 0.00788771 for each). Their m values, representing
the likelihood of functional relevance, were 0.978 and 0.995,
respectively. Interestingly, the set of AD associated SNPs that
were identified from early-onset FAD (Table 1) was in linkage
disequilibrium with the eQTL identified in the frontal cortex tis-
sues in the GTEx dataset (Figure S2), suggesting that the identi-
fied SNPs (or adjacent SNPs) are likely to influence SYNJ1
expression.
Elevated SYNJ1 Levels Are Associated with Synaptic
Deficits in DS/AD
In light of earlier reports that SYNJ1 levels are elevated in individ-
uals at high risk for developing SAD (Zhu et al., 2015) and DS/AD
(Martin et al., 2014), our results in human FAD cohorts strongly
suggested that SYNJ1 may play a role in all three forms of AD.
This motivated us to investigate whether elevated SYNJ1 affects
cognition in an age-dependent manner, an AD hallmark. We hy-
pothesized that a large increase in SYNJ1 levels, such as the one
observed in populations at high risk for developing DS/AD
(+155% compared with age-matched disomic controls) (Martin
et al., 2014), could influence synaptic integrity. To test this hy-
pothesis, we used data previously collected on post-mortem
brain samples of individuals with DS at different ages (Martin
et al., 2014). We focused on the age range of 40–52 years,
when most individuals with DS develop AD. For each individual,
we plotted the levels of SYNJ1 against the levels of synaptophy-
sin, a pre-synaptic protein that we used as a direct measure of
synaptic integrity (Figure 1). Indeed, synaptophysin levels have
been extensively and consistently found to be decreased in indi-
viduals with AD and DS/AD (e.g., (Downes et al., 2008; Masliah
et al., 1989, 1991; Reddy et al., 2005; Terry et al., 1991).
We found that levels of SYNJ1 were inversely correlated
(p = 0.0151, R2 = 0.2862) with levels of synaptophysin; that is,
the higher the levels of SYNJ1, the more synaptic integrity was
compromised. In contrast, no such correlation (p = 0.1784,
R2 = 0.2790) was observed in younger individuals with DS (age
range 1–39 years), whose SYNJ1 levels are only mildly higher
(+36%) than those of disomic controls (Figure S3). Our results
thus strongly suggest that elevated levels of SYNJ1 observed
in populations at high risk for developing AD could directly affect
synaptic structure, function, or both.Cell Reports 23, 2967–2975, June 5, 2018 2969
Figure 1. Elevated SYNJ1 Levels Are Associated with Synaptic
Deficits in DS/AD
Western blot analysis of SYNJ1 and synaptophysin in human post-mortem
brain samples from the mid-frontal cortex (BA46) of individuals with DS, aged
40–52 years (Martin et al., 2014) (n = 20). The line represents the linear
regression (R2 = 0.29, p = 0.015). See also Figure S3 for additional information.Elevated Synj1 Levels Drive Age-Dependent
Hippocampal Cognitive Deficits
To dissect the effect of elevated levels of synaptojanin 1 on
cognition, we used a transgenic mouse model overexpressing
murine Synj1, Tg(Synj1) (Voronov et al., 2008). We observed
76% more Synj1 in the brain of transgenic mice than in litter-
mate controls (wild-type [WT]) (Figure 2A). This closely recapit-
ulates the overexpression levels (+73%) described in APOE4
carriers with early AD (clinical dementia rating [CDR] 0.5–1)
(Zhu et al., 2015) but is milder than the overexpression levels
in individuals with DS/AD (+155% compared with age-matched
disomic controls) (Martin et al., 2014). Indeed, we found that
levels of pre-synaptic (synaptophysin) and post-synaptic (PSD
95) proteins were not altered in the hippocampi of 19-month-
old transgenic versus WT animals (Figure S4A), suggesting no
gross synaptic loss, even in older animals. Tg(Synj1) mice
thus appeared as a good model system to dissect the effect
of elevated levels of Synj1 on synaptic dysfunction and cogni-
tive deficits.
We focused on two hippocampus-dependent behavior tasks,
as this region is critically affected in AD (Stoub et al., 2006), and
investigated whether the performance of transgenic Tg(Synj1)
mice in these tasks declined with age. We first used the radial
arm water maze (RAWM) paradigm to probe working memory.
At 9 months, Tg(Synj1) and WT mice performed similarly in the
RAWM test (Figure 2B). In contrast, at 19 months, Tg(Synj1)
mice showed a significantly higher number of errors in the
RAWM compared with WT mice (Figure 2B). Although WT mice
experienced cognitive decline with age, age-dependent cogni-
tive deficits were significantly more pronounced in Tg(Synj1)
than in WT littermates (188% of normal aging; Figure 2C).
Although 19-month-old Tg(Synj1) swam slightly slower than2970 Cell Reports 23, 2967–2975, June 5, 2018age-matchedWTmice, their ability to reach a visible platform re-
mained unchanged (Figure S4B), ruling out any visual or motiva-
tional impairment.
To assess whether other forms of learning were impaired in
transgenic mice, we used a fear conditioning (FC) paradigm.
Whereas contextual fear learning depends on both hippocam-
pus and amygdala, cued testing only depends on the amygdala.
No difference in contextual or cued freezing behavior was
observed between Tg(Synj1) and WT mice at 9 months (Fig-
ure 2D). However, at 19 months, Tg(Synj1) mice showed a
specific decrease in freezing in contextual but not in cued condi-
tioning compared with WT mice, suggesting hippocampal but
not amygdala impairment (Figure 2E). Taken together, our
behavior results strongly suggest that increased levels of Synj1
drive age-dependent cognitive deficits in the hippocampus.
Elevated Synj1 Levels Trigger Hippocampal Place Cell
Dysfunction
We then pursued the functional basis underlying hippocampal
cognitive deficits in older Tg(Synj1) animals. Specifically, we
investigated whether increased Synj1 levels could alter hippo-
campal synaptic function using in vivo electrophysiological re-
cordings in the hippocampus (Figure S5A). Although the firing
of hippocampal inhibitory neuronswas not affected (Figure S5B),
the average and peak firing rates of hippocampal excitatory
neurons were significantly increased in Tg(Synj1) mice (+57%
and +67% increases compared with WT, respectively; Fig-
ure 3A). Because these recorded excitatory neurons were place
cells (Hussaini et al., 2011) (Figure 3B), we asked whether place
field properties were altered in transgenic animals. The average
and peak field firing rates were increased in Tg(Synj1) mice
compared with WT (Figure 3C). The mean place field size was
comparable between transgenic animals and controls (Fig-
ure 3D). However, place field size distribution was broader in
Tg(Synj1) mice, highlighting a higher size variability in transgenic
animals (Figure 3D). Information content and spatial coherence
were comparable between transgenic and control mice (Figures
3Eand 3F). More important, the stability of place fields after 18–
24 hr was decreased by more than 3-fold in Tg(Synj1) mice (Fig-
ure 3G), suggesting a memory retention deficit.
Overall, our findings indicate that elevated levels of Synj1
trigger acute hyperexcitability as well as dramatic defects in
the spatial reproducibility of place fields in the hippocampus of
older Tg(Synj1) animals. Our data from mouse model systems
strongly argue that the elevated levels of SYNJ1 observed in
DS/AD and SAD could be the cause of the age-dependent
long-term memory defects observed in AD patients.
DISCUSSION
The present study addressed whether the elevated levels of
SYNJ1 observed in populations at high risk to develop AD could
be a common feature underlying age-dependent cognitive defi-
cits. This study is supported by earlier reports in AD mouse
models that described an important role for synaptojanin 1 in
mechanisms of neuronal toxicity (Berman et al., 2008; Cossec
et al., 2012) and human data that showed elevated levels of
SYNJ1 in APOE4 carriers (Zhu et al., 2015) and in individuals
Figure 2. Overexpression of Synj1 Drives
Hippocampal-Dependent Cognitive Deficits
in an Age-Dependent Manner
(A) Western blot analysis of Synj1 in 19-month-old
WT and Tg(Synj1) mice (n = 4). Tubulin was used as
an equal loading marker. Synj1 protein levels were
76% higher in Tg(Synj1) (1.76 ± 0.11) than in WT
(1.00 ± 0.05) mice. ***p < 0.001 in unpaired Stu-
dent’s t test.
(B) Performance of WT and Tg(Synj1) mice at 9
(n = 8 WT and 7 Tg[Synj1] mice) and 19 (n = 9 mice
for both genotypes) months in the radial arm water
maze (RAWM). Mice were administered 30 trials
over a 2-day period, and the number of errors was
averaged over three trials. Two-way ANOVA re-
vealed an interaction between genotype and trial
block at 19 months but not at 9 months. ns,
p > 0.05, and **p < 0.01 for the overall effect of
genotype in two-way ANOVA. In trial 6, ***p < 0.001
for the effect of genotype in two-way ANOVA with
Bonferroni post-test.
(C) Age-dependent modification of RAWM perfor-
mance of WT and Tg(Synj1) mice. Age-dependent
cognitive deficits were more severe in Tg(Synj1)
mice (188 ± 25%, n = 9) than in WT mice (100 ±
20%, n = 9). *p < 0.05 in unpaired Student’s t test.
(D and E) Freezing response in the contextual and
cued FC paradigm in (D) 9-month-old WT (n = 10)
and Tg(Synj1) (n = 9) mice and in (E) 19-month-old
WT (n = 11) and Tg(Synj1) (n = 7) mice. *p < 0.05 in
unpaired Student’s t test.
Data are represented as mean ± SEM. See also
Figure S4 for additional information.with DS/AD (Martin et al., 2014) and answers two previously un-
addressed questions. Specifically, this work addresses whether
SYNJ1 is associated with human FAD as well as whether
elevated levels of Synj1 directly affect cognition in an age-
dependent manner.
Our targeted gene approach extended the relevance of alter-
ations in SYNJ1 to FAD by showing that variants in SYNJ1 are
associated with age of onset and long-term memory deficits in
an early-onset FAD cohort of Caribbean Hispanic families with
the PSEN1-G206A founder mutation. We further showed that
variants in SYNJ1 are also associated with age of onset in the
EFIGA cohort of late-onset FAD. Our findings highlight the rele-
vance of studying the impact of SYNJ1 alterations on memory
performance for AD. We observed that in DS/AD brain samples,
higher SYNJ1 levels correlated with compromised synaptic
integrity. We then mimicked milder SYNJ1 overexpression
levels, as observed in SAD, in a previously described transgenic
mouse model (Voronov et al., 2008). Three- to 4-month-old mice
with a mixed FVB/C57BL/6 background showed no anxiety-
related behavior (Voronov et al., 2008). They also did not exhibit
deficits in theMorris watermaze paradigmbut performed slightlyCellworse than control animals in the reverse
platform test variation of this paradigm
(Voronov et al., 2008). For this study, the
BAC was backcrossed on the C57BL/6
background for eight generations, andwe focused on older, and thus more AD-relevant, animals. Our
RAWM and FC behavior studies showed that increased levels
of Synj1 triggered age-dependent cognitive deficits in the hippo-
campus of transgenic Tg(Synj1) mice. Our findings support that
increased levels of Synj1 did not impair learning per se in older
animals, as evident from the non-null slope in trials 1–5 and trials
6–10 in the RAWM, but caused a specific defect in long-term
memory retention. This is particularly well illustrated by the
very large number of errors in the first trial of day 2 (trial 6; Fig-
ure 2B) in the RAWM as well as by the reduced freezing behavior
after 24 hr in contextual conditioning (Figure 2E). Using in vivo re-
cordings, we showed that this defect is due to hippocampal hy-
perexcitability and, more specifically, to a dramatic alteration in
the spatial reproducibility of hippocampal place fields. Taken
together, our data strongly argue that the elevated levels of
SYNJ1 observed in populations at high risk to develop AD could
be sufficient to trigger age-dependent long-term memory reten-
tion impairment, a signature trait of the cognitive deficits
observed in AD patients.
A key finding of our study is that levels of synaptojanin 1 can
regulate the properties, specifically the spatial reproducibility,Reports 23, 2967–2975, June 5, 2018 2971
Figure 3. Overexpression of Synj1 Results in Hippocampal Hyper-
excitability and Decreased Place Field Stability
(A) Left: average firing rate of hippocampal excitatory (pyramidal) neurons in
24-month-old Tg(Synj1) mice (3.2 ± 0.2 Hz, n = 72 neurons from six animals)
and controls (2.0 ± 0.2 Hz, n = 98 neurons from five animals). Right: peak firing
rate of pyramidal neurons in Tg(Synj1) mice (9.3 ± 0.7 Hz) and controls (5.6 ±
0.4 Hz). ***p < 0.001 in Mann Whitney test.
(B) Representative examples of firing rate maps showing place fields obtained
after WT and Tg(Synj1) mice explored a 50-cm-diameter cylindrical arena for
20min. The firing rate is represented by a heatmap ranging from blue (no firing)
to red (peak firing). White spaces indicate locations not visited by the animal.
(C) Left: average field firing rate in Tg(Synj1) mice (3.8 ± 0.3 Hz, n = 72 neurons)
and controls (2.2 ± 0.2 Hz, n = 98 neurons). Right: peak field firing rate in
Tg(Synj1) mice (9.2 ± 0.7 Hz) and controls (5.5 ± 0.4 Hz). ***p < 0.001 in Mann-
Whitney test.
(D) Size of place fields in Tg(Synj1) andWTmice. The average size (left) of place
fields was comparable (p > 0.05 in Mann-Whitney test) between Tg(Synj1)
(1,066 ± 58 cm2, n = 72 neurons) and WT (1,043 ± 24 cm2, n = 98 neurons)
mice, although the distribution (right) of place field sizes was significantly
different (***p < 0.001 in chi-square test).
(E) Comparable (p > 0.05, Mann-Whitney test) information content between
Tg(Synj1) (0.29 ± 0.05 bits/spike, n = 72) andWT (0.19 ± 0.03 bits/spike, n = 98)
neurons.
(F) Similar spatial coherence (p > 0.05, Mann-Whitney test) between Tg(Synj1)
(2.25 ± 0.03, n = 72) and WT (2.21 ± 0.02, n = 98) neurons.
(G) Place field stability at 18–24 hr was significantly decreased (*p < 0.05 in
unpaired Student’s t test) in Tg(Synj1) mice (0.05 ± 0.04, n = 20 neurons)
compared with controls (0.17 ± 0.03, n = 24 neurons).
2972 Cell Reports 23, 2967–2975, June 5, 2018of hippocampal place fields. Indeed, although the unique role of
Synj1 in synaptic function has been very well described (Cre-
mona et al., 1999; Gong and De Camilli, 2008; Kim et al., 2002;
Mani et al., 2007; Verstreken et al., 2003), how it translates to hip-
pocampal spatial memory encoding remained unknown. This is
particularly important in light of the emerging role of SYNJ1 as
a crucial regulator in neurodegenerative diseases, including AD
and Parkinson’s disease. Remarkably, mutations in SYNJ1
have recently been reported to be associated with early-onset
progressive parkinsonism (Kirola et al., 2016; Krebs et al.,
2013; Olgiati et al., 2014; Quadri et al., 2013). These mutations
affect the role of synaptojanin 1 at the synapse and result in de-
fects in clathrin uncoating (Cao et al., 2017), in autophagosome
maturation (Vanhauwaert et al., 2017), or both.
Another central finding highlights the importance of SYNJ1 in
AD. Our results establish synaptojanin 1 as a key regulator of
age-related cognitive decline and support that modifications of
SYNJ1 levels could be a unifying feature of memory deficits
observed in the three types of AD (familial, sporadic, and DS/
AD). To our knowledge, the only other protein described to be
involved in all three forms of AD is APP. Indeed, APP can be
mutated in FAD, it maps to Hsa21, and variants in the APP
gene promoter region are a risk factor for SAD (Guyant-Mare´chal
et al., 2007; Lv et al., 2008).
Our findings thus strongly argue that developing specific
SYNJ1 inhibitors is an attractive therapeutic strategy for AD.
This is supported by earlier reports showing that genetically
decreasing Synj1 levels rescues cognitive deficits in murine
models of FAD (APP and PSEN1 mutations) (McIntire et al.,
2012; Zhu et al., 2013) and SAD (ApoE4 knockins) (Zhu et al.,
2015). If successful, this therapy would be protective against
both toxic effects of oligomeric Ab (Berman et al., 2008) and
cognitive decline linked to age and could be extended to all three
forms of AD. Importantly, SYNJ1 can serve as an ideal drug
target, as it is a brain-specific phosphatase. That is, its activity
can be targeted by small molecules without affecting its struc-
tural roles, with limited secondary effects on peripheral organs.
Our findings also provide disease-relevant functional readouts,
e.g., accuracy of hippocampal spatial encoding, to evaluate
the efficacy of these future drugs.
EXPERIMENTAL PROCEDURES
Genetics and Population
Early-Onset FAD
For the genetic study of early-onset FAD, all participating subjects were at
least 35 years of age. FAD patients, with the age at onset <65 years, met the
research criteria of the National Institute of Neurological and Communicative
Disorders and Stroke (NINCDS) and the AD and Related Disorders Association
(ADRDA) for probable or possible AD (McKhann et al., 1984). We studied 305
family members from 45 Caribbean Hispanic families that had at least one
G206A foundermutation in the PSEN1 gene (PSEN1-G206A), in which approx-
imately 50% of the family members were carriers of the PSEN1-G206A (Athan
et al., 2001; Lee et al., 2015).
To obtain WGS data on all family members while minimizing sequencing
costs, we first selected two to four highly informative family members from
each branch of the pedigree using the GIGI algorithm (Cheung et al., 2013)Data are represented as mean ± SEM. See also Figure S5 for additional
information.
and performed WGS on the Illumina HiSeq 2500 platform. In addition, we also
performedGWASon all clinically evaluated family members in the pedigree. To
generate WGS data for all family members, we applied SHAPIT2 (Delaneau
et al., 2013) and IMPUTE2 (Howie et al., 2009) to impute sequence data into
GWAS in family members who were not sequenced. To ensure high-quality
imputation in this admixed cohort, we used in-house WGS data generated
from 608 Caribbean Hispanics from Puerto Rico and the Dominican Republic,
plus the 1000 Genomes data (n = 2,504) as a reference panel. Standard quality
control (QC) procedures were performed (Howie et al., 2012). To determine
whether genetic variants in SYNJ1 were associated with variation in age at
onset of AD and memory traits, specifically global memory, long-term recall
and delayed recall, we first performed a gene-wise analysis while taking into
account AD status, sex, PSEN1-G206A, level of education, APOE4, and prin-
cipal components 1–3, as implemented in FamSKAT (Chen et al., 2013) for
each trait. For the purpose of analysis, we followed the convention of survival
analysis and defined age at onset of AD as follows: if affected, age at onset was
used as the age at onset; if unaffected, age at last examination was used. To
determine whether certain variants within SYNJ1were significantly associated
with the traits, we performed a SNP-wise analysis for the variants in SYNJ1
while controlling for the same set of covariates as well as kinship coefficient
to take into account non-independence among family members. Linear mixed
modeling was performed using R (http://cran.r-project.org/web/packages/
kinship2/kinship2.pdf).
Replication in Late-Onset AD
To determine whether the observed genetic association between SYNJ1 and
early-onset FAD was present in late-onset AD as well, we examined the role of
SYNJ1 by evaluating the EFIGA cohort, which comprises both Caribbean His-
panic families with late-onset AD (Lee et al., 2011; Romas et al., 2002) and un-
related Caribbean Hispanics with SAD (Tosto et al., 2015) (see Table S1 for
their characteristics). Genotyping data were obtained using multiple batches
of SNP microarray platforms (see Table S3). We performed a sliding-window
haplotype analysis using the GMMAT algorithm (Chen et al., 2016), taking
three or four tagSNPs at a time. We then compared the mean age at onset
associated with the risk haplotype.
Recruitment, informed consent, and study procedures for the above two
studies were approved by the institutional review boards of the Columbia Uni-
versity Medical Center (AAA R5816 for the Genetic modifier study and AAA
PO477 for EFIGA).
Human Subjects, Autopsy Brain Tissue, and Western Blot
Characteristics of autopsy cases, as well as brain tissue preparation protocol
and western blotting procedures, were previously described in full detail (Mar-
tin et al., 2014).
Mouse Models
Two different mouse models were tested: (1) Tg(Synj1) mice and (2) their
C57BL/6 control littermates (WT). The Tg(Synj1) line was a kind gift from the
Antonarakis lab. It was generated on the FVB background using mouse BAC
RPCI-23 402J16, as described previously (Voronov et al., 2008). This BAC
also contains two additional complete genes, the mouse orthologs of
C21orf59 and C21orf66 (Voronov et al., 2008). The expression of C21orf59 is
enriched in the cerebellum (https://gtexportal.org/home/gene/C21ORF59).
The C21orf59 protein controls primary cilia motility and polarization (Austin-
Tse et al., 2013; Jaffe et al., 2016). The expression of C21orf66, also called
PAXBP1, is enriched in the cerebellum too (https://gtexportal.org/home/
gene/PAXBP1). PAXBP1 is an adaptor protein linking the transcription factors
PAX3 and PAX7 to the histone methylation machinery in muscle precursor
cells (Diao et al., 2012). A variant of PAXBP1 was recently linked to myopathic
hypotonia (Alharby et al., 2017). Contributing effects from these genes cannot
be excluded. For this study, the BAC was backcrossed on the C57BL/6 back-
ground for eight generations. Genotypes were assessed using PCR. All ani-
mals were hemizygous for the BAC transgene. All procedures were performed
following NIH guidelines in accordance with Institutional Animal Care and Use
Committee (IACUC) protocols. Tests were performed on 4–14 mice for each
genotype group. All experiments were performed blind with respect to the ge-
notype. Behavior experiments were performed on two age groups: 9 months
(range 8–11 months) and 19 months (range 18–22 months). Because of tech-nical considerations, in vivo electrophysiology recordings were performed on a
larger age range (19–31 months), with an average age of 24 months at
recording. All experiments were performed on age-matched mice for each ge-
notype group. Separate tests were performed for males and females. Because
no sex-specific differences were found, results from both genders were
pooled.
Statistical Analysis
Statistical calculations were performed usingGraphPad Prism version 5.02. All
data are expressed asmean ±SEM. Inmost cases, when comparing two sam-
ples, two-tailed Student’s t test was performed. When variances were not
comparable, Welch’s correction was applied. When the distribution could
not be assumed to be Gaussian, we used a non-parametric Mann-Whitney
test. When more samples were compared and Bartlett’s test showed that var-
iances could be compared, we used one-way ANOVAwith Dunnett’s post-test
or two-way ANOVA with the Bonferroni post-test. If variances could not be
compared (p value in Bartlett’s test < 0.05), we used t tests. When more sam-
ples were compared and when the distribution could not be assumed to be
Gaussian, we used the Kruskal-Wallis test. The chi-square test was used to
compare distributions. Outliers, defined as values that were superior to
(mean + 3 SDs) or inferior to (mean  3 SDs) were excluded.
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